Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Sotio Biotech Inc.
Neonc Technologies, Inc.
ImmunityBio, Inc.
OncoC4, Inc.
Seagen Inc.
Salubris Biotherapeutics Inc
University of Florida
Fate Therapeutics
Xencor, Inc.
Incyte Corporation
MultiVir, Inc.
Incyte Corporation
Case Comprehensive Cancer Center